Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal
Few studies compare the clinical effectiveness of the three anti-CGRP mAbs. Moreover, no studies compare their efficacy during suspension and reprisal. Our study aimed to compare the efficacy of migraine frequency, intensity, and symptomatic medication intake during the first year of therapy, a 1-mo...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2023-11, Vol.12 (23), p.7329 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 23 |
| container_start_page | 7329 |
| container_title | Journal of clinical medicine |
| container_volume | 12 |
| creator | Tereshko, Yan Dal Bello, Simone Pez, Sara Belgrado, Enrico Lettieri, Christian Ercole, Bruno Hector Cellante, Giulia Del Regno, Caterina Sportelli, Giuseppe Ermanis, Giovanni Versace, Salvatore Merlino, Giovanni Gigli, Gian Luigi Valente, Mariarosaria |
| description | Few studies compare the clinical effectiveness of the three anti-CGRP mAbs. Moreover, no studies compare their efficacy during suspension and reprisal. Our study aimed to compare the efficacy of migraine frequency, intensity, and symptomatic medication intake during the first year of therapy, a 1-month suspension period, and a 3-month drug reprisal.
A total of 160 migraineurs (chronic and high-frequency episodic) were treated with anti-CGRP mAbs (49 with fremanezumab, 55 with erenumab, and 55 with galcanezumab) for 12 months. They discontinued the therapy for 1 month and then reprised the therapy. In the three groups, we analyzed and compared the migraine days per month, migraine intensity, and symptomatic medication intake per month at baseline, 3-month, 6-month, and 12-month follow-up. We also compared these variables during the 1-month suspension and 3 months after the reprisal of the therapy. We compared the data and evaluated the response rate (>50% reduction in migraine days per month) at different follow-ups. This comparison was also performed separately for chronic and high-frequency episodic migraineurs.
There was no statistical difference in monthly migraine days, intensity, or symptomatic medication intake per month at the different follow-ups. Moreover, there was no difference in the response rate overall. However, in chronic migraineurs treated with galcanezumab, the response rate was higher during the 1-month suspension when compared to fremanezumab and erenumab. In high-frequency episodic migraineurs, fremanezumab had a higher response rate at 12-month follow-up when compared to galcanezumab and erenumab.
In our study, the three anti-CGRP mAbs presented a similar response, with no significant differences, during the first year of therapy, the suspension period, and 3 months after the drug reprisal. The response rate during the 1-month suspension period in chronic migraineurs may be higher with galcanezumab. |
| doi_str_mv | 10.3390/jcm12237329 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2902950801</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A775890583</galeid><sourcerecordid>A775890583</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-4aba5427e14640bb15f56b25641dddf7a17a6abd32a697cd738ec4da8fae854e3</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEolXpiTuyxAWJpvgjiW1uq1VbkFpRteXAKZrY465XSby1E6T9G_xivLSFgrAPHs887yt_TFG8ZvRYCE0_rM3AOBdScP2s2OdUypIKJZ4_ifeKw5TWNA-lKs7ky2JPKNqoXNovfizDsIEIk_-O5Hqa7ZYER6YVkhPnvAHza78YJ18uz64uybDoEgkjufC3EfyIc0wfcxn6bfLpUXrqY5rIN4S4y9ysMMJme0RYeRHGaUWu57TBMflsc4nRB3tEYLTkCjfRJ-hfFS8c9AkPH9aD4uvpyc3yU3n-5ezzcnFeGiH1VFbQQV1xiaxqKtp1rHZ10_G6qZi11klgEhrorODQaGmsFApNZUE5QFVXKA6Kd_e-mxjuZkxTO_hksO9hxDCnlmvKdU0VZRl9-w-6DnPMt86U0rqqFef6D3ULPbZ-dGGKYHam7ULKWmlaK5Gp4_9QeVocvAkjOp_zfwne3wtMDClFdG1-pwHitmW03TVB-6QJMv3m4ahzN6D9zT5-ufgJKf2qiQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2899458229</pqid></control><display><type>article</type><title>Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Tereshko, Yan ; Dal Bello, Simone ; Pez, Sara ; Belgrado, Enrico ; Lettieri, Christian ; Ercole, Bruno Hector ; Cellante, Giulia ; Del Regno, Caterina ; Sportelli, Giuseppe ; Ermanis, Giovanni ; Versace, Salvatore ; Merlino, Giovanni ; Gigli, Gian Luigi ; Valente, Mariarosaria</creator><creatorcontrib>Tereshko, Yan ; Dal Bello, Simone ; Pez, Sara ; Belgrado, Enrico ; Lettieri, Christian ; Ercole, Bruno Hector ; Cellante, Giulia ; Del Regno, Caterina ; Sportelli, Giuseppe ; Ermanis, Giovanni ; Versace, Salvatore ; Merlino, Giovanni ; Gigli, Gian Luigi ; Valente, Mariarosaria</creatorcontrib><description>Few studies compare the clinical effectiveness of the three anti-CGRP mAbs. Moreover, no studies compare their efficacy during suspension and reprisal. Our study aimed to compare the efficacy of migraine frequency, intensity, and symptomatic medication intake during the first year of therapy, a 1-month suspension period, and a 3-month drug reprisal.
A total of 160 migraineurs (chronic and high-frequency episodic) were treated with anti-CGRP mAbs (49 with fremanezumab, 55 with erenumab, and 55 with galcanezumab) for 12 months. They discontinued the therapy for 1 month and then reprised the therapy. In the three groups, we analyzed and compared the migraine days per month, migraine intensity, and symptomatic medication intake per month at baseline, 3-month, 6-month, and 12-month follow-up. We also compared these variables during the 1-month suspension and 3 months after the reprisal of the therapy. We compared the data and evaluated the response rate (>50% reduction in migraine days per month) at different follow-ups. This comparison was also performed separately for chronic and high-frequency episodic migraineurs.
There was no statistical difference in monthly migraine days, intensity, or symptomatic medication intake per month at the different follow-ups. Moreover, there was no difference in the response rate overall. However, in chronic migraineurs treated with galcanezumab, the response rate was higher during the 1-month suspension when compared to fremanezumab and erenumab. In high-frequency episodic migraineurs, fremanezumab had a higher response rate at 12-month follow-up when compared to galcanezumab and erenumab.
In our study, the three anti-CGRP mAbs presented a similar response, with no significant differences, during the first year of therapy, the suspension period, and 3 months after the drug reprisal. The response rate during the 1-month suspension period in chronic migraineurs may be higher with galcanezumab.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm12237329</identifier><identifier>PMID: 38068383</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Care and treatment ; Chi-square test ; Clinical medicine ; Comparative analysis ; Contingency tables ; Drug therapy ; Headaches ; Health aspects ; Migraine ; Monoclonal antibodies ; Patient outcomes ; Patients ; Peptide hormones ; Peptides ; Statistical analysis</subject><ispartof>Journal of clinical medicine, 2023-11, Vol.12 (23), p.7329</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c379t-4aba5427e14640bb15f56b25641dddf7a17a6abd32a697cd738ec4da8fae854e3</cites><orcidid>0009-0001-1807-7589 ; 0000-0002-4200-761X ; 0000-0003-2062-2547 ; 0000-0002-6525-9529 ; 0000-0001-8013-5877 ; 0009-0003-4964-6718</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38068383$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tereshko, Yan</creatorcontrib><creatorcontrib>Dal Bello, Simone</creatorcontrib><creatorcontrib>Pez, Sara</creatorcontrib><creatorcontrib>Belgrado, Enrico</creatorcontrib><creatorcontrib>Lettieri, Christian</creatorcontrib><creatorcontrib>Ercole, Bruno Hector</creatorcontrib><creatorcontrib>Cellante, Giulia</creatorcontrib><creatorcontrib>Del Regno, Caterina</creatorcontrib><creatorcontrib>Sportelli, Giuseppe</creatorcontrib><creatorcontrib>Ermanis, Giovanni</creatorcontrib><creatorcontrib>Versace, Salvatore</creatorcontrib><creatorcontrib>Merlino, Giovanni</creatorcontrib><creatorcontrib>Gigli, Gian Luigi</creatorcontrib><creatorcontrib>Valente, Mariarosaria</creatorcontrib><title>Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Few studies compare the clinical effectiveness of the three anti-CGRP mAbs. Moreover, no studies compare their efficacy during suspension and reprisal. Our study aimed to compare the efficacy of migraine frequency, intensity, and symptomatic medication intake during the first year of therapy, a 1-month suspension period, and a 3-month drug reprisal.
A total of 160 migraineurs (chronic and high-frequency episodic) were treated with anti-CGRP mAbs (49 with fremanezumab, 55 with erenumab, and 55 with galcanezumab) for 12 months. They discontinued the therapy for 1 month and then reprised the therapy. In the three groups, we analyzed and compared the migraine days per month, migraine intensity, and symptomatic medication intake per month at baseline, 3-month, 6-month, and 12-month follow-up. We also compared these variables during the 1-month suspension and 3 months after the reprisal of the therapy. We compared the data and evaluated the response rate (>50% reduction in migraine days per month) at different follow-ups. This comparison was also performed separately for chronic and high-frequency episodic migraineurs.
There was no statistical difference in monthly migraine days, intensity, or symptomatic medication intake per month at the different follow-ups. Moreover, there was no difference in the response rate overall. However, in chronic migraineurs treated with galcanezumab, the response rate was higher during the 1-month suspension when compared to fremanezumab and erenumab. In high-frequency episodic migraineurs, fremanezumab had a higher response rate at 12-month follow-up when compared to galcanezumab and erenumab.
In our study, the three anti-CGRP mAbs presented a similar response, with no significant differences, during the first year of therapy, the suspension period, and 3 months after the drug reprisal. The response rate during the 1-month suspension period in chronic migraineurs may be higher with galcanezumab.</description><subject>Care and treatment</subject><subject>Chi-square test</subject><subject>Clinical medicine</subject><subject>Comparative analysis</subject><subject>Contingency tables</subject><subject>Drug therapy</subject><subject>Headaches</subject><subject>Health aspects</subject><subject>Migraine</subject><subject>Monoclonal antibodies</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Peptide hormones</subject><subject>Peptides</subject><subject>Statistical analysis</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkk1v1DAQhiMEolXpiTuyxAWJpvgjiW1uq1VbkFpRteXAKZrY465XSby1E6T9G_xivLSFgrAPHs887yt_TFG8ZvRYCE0_rM3AOBdScP2s2OdUypIKJZ4_ifeKw5TWNA-lKs7ky2JPKNqoXNovfizDsIEIk_-O5Hqa7ZYER6YVkhPnvAHza78YJ18uz64uybDoEgkjufC3EfyIc0wfcxn6bfLpUXrqY5rIN4S4y9ysMMJme0RYeRHGaUWu57TBMflsc4nRB3tEYLTkCjfRJ-hfFS8c9AkPH9aD4uvpyc3yU3n-5ezzcnFeGiH1VFbQQV1xiaxqKtp1rHZ10_G6qZi11klgEhrorODQaGmsFApNZUE5QFVXKA6Kd_e-mxjuZkxTO_hksO9hxDCnlmvKdU0VZRl9-w-6DnPMt86U0rqqFef6D3ULPbZ-dGGKYHam7ULKWmlaK5Gp4_9QeVocvAkjOp_zfwne3wtMDClFdG1-pwHitmW03TVB-6QJMv3m4ahzN6D9zT5-ufgJKf2qiQ</recordid><startdate>20231126</startdate><enddate>20231126</enddate><creator>Tereshko, Yan</creator><creator>Dal Bello, Simone</creator><creator>Pez, Sara</creator><creator>Belgrado, Enrico</creator><creator>Lettieri, Christian</creator><creator>Ercole, Bruno Hector</creator><creator>Cellante, Giulia</creator><creator>Del Regno, Caterina</creator><creator>Sportelli, Giuseppe</creator><creator>Ermanis, Giovanni</creator><creator>Versace, Salvatore</creator><creator>Merlino, Giovanni</creator><creator>Gigli, Gian Luigi</creator><creator>Valente, Mariarosaria</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0001-1807-7589</orcidid><orcidid>https://orcid.org/0000-0002-4200-761X</orcidid><orcidid>https://orcid.org/0000-0003-2062-2547</orcidid><orcidid>https://orcid.org/0000-0002-6525-9529</orcidid><orcidid>https://orcid.org/0000-0001-8013-5877</orcidid><orcidid>https://orcid.org/0009-0003-4964-6718</orcidid></search><sort><creationdate>20231126</creationdate><title>Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal</title><author>Tereshko, Yan ; Dal Bello, Simone ; Pez, Sara ; Belgrado, Enrico ; Lettieri, Christian ; Ercole, Bruno Hector ; Cellante, Giulia ; Del Regno, Caterina ; Sportelli, Giuseppe ; Ermanis, Giovanni ; Versace, Salvatore ; Merlino, Giovanni ; Gigli, Gian Luigi ; Valente, Mariarosaria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-4aba5427e14640bb15f56b25641dddf7a17a6abd32a697cd738ec4da8fae854e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Care and treatment</topic><topic>Chi-square test</topic><topic>Clinical medicine</topic><topic>Comparative analysis</topic><topic>Contingency tables</topic><topic>Drug therapy</topic><topic>Headaches</topic><topic>Health aspects</topic><topic>Migraine</topic><topic>Monoclonal antibodies</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Peptide hormones</topic><topic>Peptides</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tereshko, Yan</creatorcontrib><creatorcontrib>Dal Bello, Simone</creatorcontrib><creatorcontrib>Pez, Sara</creatorcontrib><creatorcontrib>Belgrado, Enrico</creatorcontrib><creatorcontrib>Lettieri, Christian</creatorcontrib><creatorcontrib>Ercole, Bruno Hector</creatorcontrib><creatorcontrib>Cellante, Giulia</creatorcontrib><creatorcontrib>Del Regno, Caterina</creatorcontrib><creatorcontrib>Sportelli, Giuseppe</creatorcontrib><creatorcontrib>Ermanis, Giovanni</creatorcontrib><creatorcontrib>Versace, Salvatore</creatorcontrib><creatorcontrib>Merlino, Giovanni</creatorcontrib><creatorcontrib>Gigli, Gian Luigi</creatorcontrib><creatorcontrib>Valente, Mariarosaria</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tereshko, Yan</au><au>Dal Bello, Simone</au><au>Pez, Sara</au><au>Belgrado, Enrico</au><au>Lettieri, Christian</au><au>Ercole, Bruno Hector</au><au>Cellante, Giulia</au><au>Del Regno, Caterina</au><au>Sportelli, Giuseppe</au><au>Ermanis, Giovanni</au><au>Versace, Salvatore</au><au>Merlino, Giovanni</au><au>Gigli, Gian Luigi</au><au>Valente, Mariarosaria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2023-11-26</date><risdate>2023</risdate><volume>12</volume><issue>23</issue><spage>7329</spage><pages>7329-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Few studies compare the clinical effectiveness of the three anti-CGRP mAbs. Moreover, no studies compare their efficacy during suspension and reprisal. Our study aimed to compare the efficacy of migraine frequency, intensity, and symptomatic medication intake during the first year of therapy, a 1-month suspension period, and a 3-month drug reprisal.
A total of 160 migraineurs (chronic and high-frequency episodic) were treated with anti-CGRP mAbs (49 with fremanezumab, 55 with erenumab, and 55 with galcanezumab) for 12 months. They discontinued the therapy for 1 month and then reprised the therapy. In the three groups, we analyzed and compared the migraine days per month, migraine intensity, and symptomatic medication intake per month at baseline, 3-month, 6-month, and 12-month follow-up. We also compared these variables during the 1-month suspension and 3 months after the reprisal of the therapy. We compared the data and evaluated the response rate (>50% reduction in migraine days per month) at different follow-ups. This comparison was also performed separately for chronic and high-frequency episodic migraineurs.
There was no statistical difference in monthly migraine days, intensity, or symptomatic medication intake per month at the different follow-ups. Moreover, there was no difference in the response rate overall. However, in chronic migraineurs treated with galcanezumab, the response rate was higher during the 1-month suspension when compared to fremanezumab and erenumab. In high-frequency episodic migraineurs, fremanezumab had a higher response rate at 12-month follow-up when compared to galcanezumab and erenumab.
In our study, the three anti-CGRP mAbs presented a similar response, with no significant differences, during the first year of therapy, the suspension period, and 3 months after the drug reprisal. The response rate during the 1-month suspension period in chronic migraineurs may be higher with galcanezumab.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38068383</pmid><doi>10.3390/jcm12237329</doi><orcidid>https://orcid.org/0009-0001-1807-7589</orcidid><orcidid>https://orcid.org/0000-0002-4200-761X</orcidid><orcidid>https://orcid.org/0000-0003-2062-2547</orcidid><orcidid>https://orcid.org/0000-0002-6525-9529</orcidid><orcidid>https://orcid.org/0000-0001-8013-5877</orcidid><orcidid>https://orcid.org/0009-0003-4964-6718</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2023-11, Vol.12 (23), p.7329 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2902950801 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Care and treatment Chi-square test Clinical medicine Comparative analysis Contingency tables Drug therapy Headaches Health aspects Migraine Monoclonal antibodies Patient outcomes Patients Peptide hormones Peptides Statistical analysis |
| title | Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T08%3A43%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20Study%20of%20the%20Efficacy%20of%20Anti-CGRP%20mAbs%20on%20Migraineurs:%20Analysis%20of%20the%20First%20Year%20of%20Therapy,%201-Month%20Suspension%20Period,%20and%20Reprisal&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Tereshko,%20Yan&rft.date=2023-11-26&rft.volume=12&rft.issue=23&rft.spage=7329&rft.pages=7329-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm12237329&rft_dat=%3Cgale_proqu%3EA775890583%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2899458229&rft_id=info:pmid/38068383&rft_galeid=A775890583&rfr_iscdi=true |